Alan Tan

Like

If we ever get to a point where we're able to intensify patients in kidney cancer too, why are we giving them single agent Pembro?

Shouldn't we be intensifying these patients like, you know, with a TKI or something like that?

So I think that's the future of trials and Matt Golski's trial is doing that.

Who knows if LAG-3 is going to pan out in bladder cancer, but at least it's randomizing to an intensification, right?

Yeah.

Speaking of precision medicine and looking at other biomarkers, like ctDNA is a promising one, but there's other biomarkers.

So do you guys, up front, when you guys see a patient with bladder cancer, how do you prioritize testing?

Do you use your tissue for ctDNA first, or do you want to test it for comprehensive genomic profiling?

Yeah, so you're definitely talking about metastatic disease.

And I totally agree.

You want those biomarkers in the metastatic setting.

But in the perioperative setting, you're not prioritizing NGS for that setting, right?

Yes, for sure.

One more thing before we wrap up the perioperative setting.

So we talked about the accelerated approval.

I mean, it was faster than EV Pembro in the metastatic setting.

That was like right after Christmas.

That was a Christmas gift for us.

But we already have EV Pembro approved based on Keynote 905, which is pretty amazing.